A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Sucroferric Oxyhydroxide (Velphoro)

Phosphate Binder class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2013-11-27
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$439.3M in CY2024 Part D spend157K claims · 39K beneficiaries · 329 plans surveyed

Lowest NADAC
$17.11/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$17.11
Across all dosage forms in distribution.
Highest NADAC
$17.11
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Sucroferric Oxyhydroxide used for?

Sucroferric Oxyhydroxide is a Phosphate Binder medication tracked in Medicare Part D.

Is there a generic for Sucroferric Oxyhydroxide?

No. Sucroferric Oxyhydroxide is brand-only with no generic equivalents currently in market.

How much does my plan pay for Sucroferric Oxyhydroxide?

Across 329 Part D plans, Sucroferric Oxyhydroxide averages $17.11/unit (NADAC). Lowest available: $17.11/unit. Highest in distribution: $17.11/unit.

Is Sucroferric Oxyhydroxide on the FDA shortage list?

No. Sucroferric Oxyhydroxide is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Phosphate Binder2 alternatives in D1
01
Sevelamer
Phosphate Binder
$0.856Lowest NADAC
5Generic mfrs
$24.0MCY24 Part D spend
Compare →
02
Sevelamer Carbonate
Brand: Renvela
$0.214Lowest NADAC
16Generic mfrs
$181.9MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.